Arcus Biosciences (RCUS) Shares Outstanding (Diluted Average) (2021 - 2026)
Arcus Biosciences (RCUS) recorded quarterly Shares Outstanding (Diluted Average) of $125.4 million in Q1 2026, up 16.76% quarter-over-quarter from $107.4 million in Q4 2025, and up 27.44% on a YoY basis from $98.4 million in Q1 2025.
Arcus Biosciences (RCUS) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Arcus Biosciences' Shares Outstanding (Diluted Average) history runs 6 years deep, the most recent figure standing at $125.4 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 27.44% year-over-year to $125.4 million; the TTM figure through Mar 2026 stood at $125.4 million (up 27.44% YoY), while the FY2025 annual figure was $107.4 million, up 19.2% from the prior year.
- Shares Outstanding (Diluted Average) was $125.4 million for Q1 2026 at Arcus Biosciences, up from $107.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $125.4 million in Q1 2026 to a low of $71.2 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $87.2 million across 5 years, with a median of $86.2 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Shares Outstanding (Diluted Average) dropped 2.7% in 2022, then grew 27.44% in 2026.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $72.0 million in 2022, then rose by 2.78% to $74.0 million in 2023, then grew by 21.76% to $90.1 million in 2024, then rose by 19.2% to $107.4 million in 2025, then climbed by 16.76% to $125.4 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $125.4 million (Q1 2026), $107.4 million (Q4 2025), and $106.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | 125.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 125.40 Mn |
| Dec 31, 2025 | 107.40 Mn |
| Sep 30, 2025 | 106.50 Mn |
| Jun 30, 2025 | 106.50 Mn |
| Mar 31, 2025 | 98.40 Mn |
| Dec 31, 2024 | 90.10 Mn |
| Sep 30, 2024 | 91.40 Mn |
| Jun 30, 2024 | 88.60 Mn |
| Mar 31, 2024 | 86.20 Mn |
| Dec 31, 2023 | 74.00 Mn |
| Sep 30, 2023 | 74.60 Mn |
| Jun 30, 2023 | 73.10 Mn |
| Mar 31, 2023 | 73.00 Mn |
| Dec 31, 2022 | 72.00 Mn |
| Sep 30, 2022 | 71.80 Mn |
| Jun 30, 2022 | 71.50 Mn |
| Mar 31, 2022 | 71.20 Mn |
| Dec 31, 2021 | 74.00 Mn |